COMP <GO>
PAHC vs JNJ // GROSS PROFIT MARGIN
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: PAHC 3
— JNJ 9
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
gross-margins
30.90%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 30.90% | 67.90% | -37.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 25.50% | -15.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 19.2x | 18.5x | +0.70 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 2.97% | +2.11 | PAHC | /fcf-yield <GO> |
| Operating Margin | 8.50% | 34.70% | -26.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 28.50% | -24.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 6.00% | +21.40 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.00% | +1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | 5.59 | -2.72 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 62.1 | -5.20 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | 23.0x | +4.50 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $662.49B | -$660.91B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | JNJ REV | PAHC GROSS % | JNJ GROSS % | PAHC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $94.19B | 30.9% | 67.9% | $80.1M | $19.70B |
| FY 2024 | $1.02B | $88.82B | 30.8% | 69.1% | $87.6M | $19.84B |
| FY 2023 | $977.9M | $85.16B | — | — | $13.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
JNJ // BETA 1.08